EA201492262A1 - Конструкция пептидного каркаса - Google Patents
Конструкция пептидного каркасаInfo
- Publication number
- EA201492262A1 EA201492262A1 EA201492262A EA201492262A EA201492262A1 EA 201492262 A1 EA201492262 A1 EA 201492262A1 EA 201492262 A EA201492262 A EA 201492262A EA 201492262 A EA201492262 A EA 201492262A EA 201492262 A1 EA201492262 A1 EA 201492262A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- construction
- methods
- relates
- peptide frame
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 238000010276 construction Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 241000724252 Cucumber mosaic virus Species 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
- G01N2333/04—Varicella-zoster virus
- G01N2333/045—Cytomegalovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/186—Hepatitis C; Hepatitis NANB
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261656256P | 2012-06-06 | 2012-06-06 | |
| PCT/EP2013/061751 WO2013182661A1 (en) | 2012-06-06 | 2013-06-06 | Peptides derived from viral proteins for use as immunogens and dosage reactants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201492262A1 true EA201492262A1 (ru) | 2015-08-31 |
Family
ID=48577073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201492262A EA201492262A1 (ru) | 2012-06-06 | 2013-06-06 | Конструкция пептидного каркаса |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10501499B2 (https=) |
| EP (1) | EP2859011B1 (https=) |
| JP (1) | JP6310909B2 (https=) |
| KR (1) | KR20150018870A (https=) |
| CN (1) | CN104619718A (https=) |
| AU (1) | AU2013273482A1 (https=) |
| BR (1) | BR112014030466A2 (https=) |
| CA (1) | CA2874923C (https=) |
| EA (1) | EA201492262A1 (https=) |
| HK (1) | HK1207871A1 (https=) |
| IL (1) | IL235891A0 (https=) |
| IN (1) | IN2014KN02769A (https=) |
| MX (1) | MX2014014683A (https=) |
| NZ (1) | NZ702146A (https=) |
| WO (1) | WO2013182661A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10342846B2 (en) * | 2013-02-04 | 2019-07-09 | University Of Notre Dame Du Lac | Nanoparticle drug delivery systems |
| TW201609152A (zh) | 2014-09-03 | 2016-03-16 | 免疫原公司 | 包含細胞結合劑及細胞毒性劑之偶聯物 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| KR20190020098A (ko) * | 2016-06-20 | 2019-02-27 | 아이에스에이 파마슈티컬즈 비.브이. | 펩타이드 백신의 제형 |
| BR112019013724A2 (pt) * | 2017-01-03 | 2020-04-14 | Emergex Vaccines Holding Limited | composições de vacina influenza universal |
| CN110548136A (zh) * | 2018-05-30 | 2019-12-10 | 王美亮 | 汉坦病毒长肽疫苗 |
| CN113784989B (zh) * | 2019-03-25 | 2024-11-15 | 免疫功坊股份有限公司 | 带有金属结合区的复合多肽及其分子构建体 |
| KR102393872B1 (ko) * | 2019-08-28 | 2022-05-04 | 엠브릭스 주식회사 | 바이러스 외피를 손상시키는 m2 단백질 유래 항바이러스 펩타이드 및 그의 용도 |
| US20230109142A1 (en) * | 2020-02-14 | 2023-04-06 | Immunor As | Corona virus vaccine |
| KR102707584B1 (ko) * | 2020-04-02 | 2024-09-19 | 조선대학교산학협력단 | 코로나바이러스 감염증１９의 진단 및 백신을 위한 재조합 뉴클레오캡시드 단백질 및 이의 용도 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4606918A (en) | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| CA1292686C (en) | 1986-10-27 | 1991-12-03 | Ze'ev Shaked | Pharmaceutical compositions of recombinant interleukin-2 and formulation process |
| CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1993001831A1 (en) | 1991-07-25 | 1993-02-04 | Idec Pharmaceuticals Corporation | Induction of cytotoxic t-lymphocyte responses |
| MA22842A1 (fr) | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
| FI945483A7 (fi) | 1992-05-23 | 1995-01-20 | Smithkline Beecham Biologicals S A | Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita |
| DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
| ATE157882T1 (de) | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| AU698962B2 (en) | 1993-09-14 | 1998-11-12 | Epimmune, Inc. | Alteration of immune response using pan DR-binding peptides |
| EP0992580B1 (en) | 1993-11-04 | 2005-03-09 | Innogenetics N.V. | Immunodominant human T-cell epitopes of Hepatitis C virus |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| AU697171B2 (en) | 1994-04-08 | 1998-10-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Hepatitis C virus core peptide for stimulation of cytotoxic T lymphocytes and diagnosis of HCV exposure |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| DE69733352T2 (de) | 1996-03-21 | 2006-04-27 | Epimmune, Inc., San Diego | Hla-a2.1 bindende peptide und deren verwendung |
| CA2250723C (en) | 1996-05-24 | 2012-07-17 | Chiron Corporation | Multiple epitope fusion protein |
| US6566330B1 (en) | 1996-10-22 | 2003-05-20 | Medical University Of South Carolina Foundation Research Development | Positively charged non-natural amino acids, methods of making and using thereof in peptides |
| GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| IL141868A0 (en) | 1998-10-05 | 2002-03-10 | M & E Biotech As | Novel methods for therapeutic vaccination |
| NO311807B1 (no) | 1999-03-04 | 2002-01-28 | Bionor Immuno As | HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV |
| EP1200109A4 (en) | 1999-07-19 | 2005-06-15 | Epimmune Inc | USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C |
| US20020076415A1 (en) | 1999-12-14 | 2002-06-20 | Jing-Hsiung Ou | Hepatitis C virus gene products |
| GB0005703D0 (en) | 2000-03-09 | 2000-05-03 | Alpharma As | Compounds |
| AU2000273396A1 (en) | 2000-09-01 | 2002-03-22 | Epimmune, Inc. | Hla binding peptides and their uses |
| NO314588B1 (no) * | 2000-09-04 | 2003-04-14 | Bionor Immuno As | HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV |
| NO314587B1 (no) | 2000-09-04 | 2003-04-14 | Bionor Immuno As | HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV |
| EP1195381A1 (de) | 2000-09-28 | 2002-04-10 | Immusystems GmbH | CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope |
| GB0026094D0 (en) | 2000-10-25 | 2000-12-13 | Imp College Innovations Ltd | Methods |
| ATE356385T1 (de) | 2002-06-10 | 2007-03-15 | Algonomics N V | Verfahren zur vorhersage der bindungsaffinität der mhc-peptid-komplexe |
| EP2301972A1 (en) * | 2002-08-12 | 2011-03-30 | The Council Of The Queensland Institute Of Medical Research | Method to prepare immunogenic lipopeptides comprising T-helper and B-cell epitopes |
| EP2402026A3 (en) | 2002-09-13 | 2012-04-18 | Intercell AG | Method for isolating hepatitis C virus peptides |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| EP1652858A1 (en) | 2004-10-28 | 2006-05-03 | Innogenetics N.V. | Peptides for inducing a CTL and/or HTL response to hepatitis C virus |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| US8252893B2 (en) | 2005-01-31 | 2012-08-28 | Board Of Trustees Of The University Of Arkansas | CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof |
| WO2008107400A1 (en) | 2007-03-02 | 2008-09-12 | Genimmune N.V. | Hcv polyepitope construct and uses thereof |
| CA2767063A1 (en) * | 2009-07-03 | 2011-01-06 | Bionor Immuno As | Novel therapeutic and diagnostic means |
| US9550811B2 (en) | 2010-12-02 | 2017-01-24 | Bionor Immuno As | Peptide scaffold design |
| US9493514B2 (en) * | 2011-01-06 | 2016-11-15 | Bionor Immuno As | Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes |
| US8618303B2 (en) * | 2011-01-07 | 2013-12-31 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
-
2013
- 2013-06-06 JP JP2015515530A patent/JP6310909B2/ja not_active Expired - Fee Related
- 2013-06-06 EA EA201492262A patent/EA201492262A1/ru unknown
- 2013-06-06 AU AU2013273482A patent/AU2013273482A1/en not_active Abandoned
- 2013-06-06 CA CA2874923A patent/CA2874923C/en active Active
- 2013-06-06 KR KR20157000273A patent/KR20150018870A/ko not_active Withdrawn
- 2013-06-06 CN CN201380039292.3A patent/CN104619718A/zh active Pending
- 2013-06-06 IN IN2769KON2014 patent/IN2014KN02769A/en unknown
- 2013-06-06 NZ NZ702146A patent/NZ702146A/en not_active IP Right Cessation
- 2013-06-06 MX MX2014014683A patent/MX2014014683A/es unknown
- 2013-06-06 HK HK15108544.7A patent/HK1207871A1/xx unknown
- 2013-06-06 WO PCT/EP2013/061751 patent/WO2013182661A1/en not_active Ceased
- 2013-06-06 EP EP13727202.7A patent/EP2859011B1/en active Active
- 2013-06-06 US US14/406,016 patent/US10501499B2/en active Active
- 2013-06-06 BR BR112014030466A patent/BR112014030466A2/pt not_active IP Right Cessation
-
2014
- 2014-11-25 IL IL235891A patent/IL235891A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013182661A1 (en) | 2013-12-12 |
| CA2874923A1 (en) | 2013-12-12 |
| BR112014030466A2 (pt) | 2017-09-12 |
| US10501499B2 (en) | 2019-12-10 |
| IN2014KN02769A (https=) | 2015-05-08 |
| IL235891A0 (en) | 2015-01-29 |
| AU2013273482A1 (en) | 2014-12-11 |
| JP2015521206A (ja) | 2015-07-27 |
| KR20150018870A (ko) | 2015-02-24 |
| EP2859011A1 (en) | 2015-04-15 |
| CA2874923C (en) | 2021-08-31 |
| NZ702146A (en) | 2016-11-25 |
| MX2014014683A (es) | 2015-02-24 |
| CN104619718A (zh) | 2015-05-13 |
| HK1207871A1 (en) | 2016-02-12 |
| EP2859011B1 (en) | 2019-12-11 |
| US20150152140A1 (en) | 2015-06-04 |
| JP6310909B2 (ja) | 2018-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201390806A1 (ru) | Конструкция пептидного каркаса | |
| EA201492262A1 (ru) | Конструкция пептидного каркаса | |
| EA201391011A1 (ru) | Мономерные и мультимерные иммуногенные пептиды | |
| EA201790630A1 (ru) | Способы получения рибозидов | |
| EA201791086A1 (ru) | Человеческие антитела против гемагглютинина вируса гриппа | |
| EA201490588A1 (ru) | Способы лечения вируса гепатита с | |
| EA201491423A1 (ru) | Соединения имидазопирролидинонов | |
| EA201391170A1 (ru) | Терапевтическое средство на основе дрожжей для лечения хронического гепатита b | |
| EA201301173A1 (ru) | Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования | |
| CO6341572A2 (es) | Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos | |
| PH12013502322A1 (en) | Hendra and nipah virus g glycoprotein immunogenic compositions | |
| EA201591164A1 (ru) | Вакцины против вируса гриппа и их применение | |
| MX360056B (es) | Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos. | |
| BR112015022790A8 (pt) | molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral | |
| EA201401281A1 (ru) | D-аминокислотные химические соединения для лечения заболеваний печени | |
| EA201391495A1 (ru) | Производные пиримидина для лечения вирусных инфекций | |
| CA2872308A1 (en) | Novel ha binding agents | |
| EA201400274A1 (ru) | Связующая молекула, обладающая нейтрализующей активностью в отношении вируса гриппа а, полученная из в-клеток человека | |
| EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
| FR2969926B1 (fr) | Arabinogalactanes, apiogalacturonanes et heteroglycanes sulfates pour le traitement des maladies causees par les virus influenza | |
| EA201500643A1 (ru) | Парвовирус свиней 5а, способы применения и вакцина | |
| IL232393A0 (en) | Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection | |
| CL2016000300A1 (es) | Métodos terapéuticos | |
| WO2014152946A3 (en) | Polypeptides for treating and/or limiting influenza infection | |
| EA201500837A1 (ru) | Парвовирус свиней 5в, способы применения и вакцина |